BlossomHill Therapeutics (BLSM) vs Eupraxia Pharmaceuticals (EPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BlossomHill Therapeutics is the larger company by market cap ($527.9 million vs $514.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLSM | EPRX |
|---|---|---|
| Share price | $16.61 | $7.78 |
| Market cap | $527.95M | $514.05M |
| 1-day change | -3.93% | +0.52% |
| YTD return | — | +3.05% |
| 1-year return | — | +29.24% |
| EPS (TTM) | $-4.70 | $-1.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.99 | $9.32 |
| 52-week low | $15.25 | $5.25 |
| Distance from 52-week high | -40.66% | -16.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +113.12% | +110.15% |
| Average volume | 263.46K | 567.95K |
| Shares outstanding | 31.78M | 66.07M |
| Employees | 69 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BlossomHill Therapeutics
BLSM stock →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Eupraxia Pharmaceuticals
EPRX stock →Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Health Care · Pharmaceuticals and Biotechnology · 49 employees
BLSM vs EPRX FAQ
Which is bigger, BlossomHill Therapeutics or Eupraxia Pharmaceuticals?
BlossomHill Therapeutics (BLSM) is larger, with a market capitalization of $527.95M compared with $514.05M for Eupraxia Pharmaceuticals (EPRX).
Are BlossomHill Therapeutics and Eupraxia Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for BlossomHill Therapeutics and Pharmaceuticals and Biotechnology for Eupraxia Pharmaceuticals.